anti-Tet Methylcytosine Dioxygenase 2 (TET2) Anticorps

The protein encoded by TET2 is a methylcytosine dioxygenase that catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine. De plus, nous expédions et et beaucoup plus de produits pour cette protéine.

afficher tous les anticorps Gène GeneID UniProt
TET2 54790 Q6N021
TET2 214133 Q4JK59
TET2 310859  
Comment commander chez anticorps-enligne
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Commandez enligne

Top anti-TET2 Anticorps sur

Showing 10 out of 107 products:

Catalogue No. Reactivité Hôte Conjugué Application Images Quantité Livraison Prix Détails
Humain Chèvre Inconjugué IHC, ELISA   100 μg 6 to 7 Days
Souris Chèvre Inconjugué ELISA   100 μg 6 to 7 Days
Humain Lapin Inconjugué IHC, WB Immunohistochemistry of paraffin-embedded rat lung using TET2 antibody at dilution of 1:100 (40x lens). 100 μL 11 to 13 Days
Humain Lapin Inconjugué IHC, WB Western blot analysis of extracts of A-431 cells, using TET2 antibody (ABIN5973320) at 1/1000 dilution. Immunohistochemistry of paraffin-embedded rat lung using TET2 antibody (ABIN5973320) at dilution of 1/100 (40x lens). 100 μL 11 to 16 Days
Humain Lapin Inconjugué IHC, WB ABIN6272933 at 1/100 staining Mouse lung tissue by IHC-P. The sample was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The sample was then blocked and incubated with the antibody for 1.5 hours at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary. Western blot analysis of extracts of HL-60 cells, using TET2 antibody. 100 μL 11 to 12 Days
Humain Souris Inconjugué IP, WB Tes2 mAb (Clone 21F11) tested by Immunoprecipitation. Tet2 detection by Immunoprecipitation. Lane 1: Input (25 µg of HL-60 whole cell lysate). Lane 2: Negative control mAb. Lane 3: Tet2 antibody at 1 µg/ml. 250 µg of HL-60 whole cell lysate per IP. Tes2 mAb (Clone 21F11) tested by Western blot. Tet2 detection by Western blot. Lane 1: HL-60 whole cell lysate (40 µg). Lane 2: Lymphoblastoid Tet2 negative (-/-) whole cell lysate (40 µg). Lane 3: Lymphoblastoid Tet2 positive (+/+) whole cell lysate (40 µg). All probed with Tet2 antibody at a 1 µg/ml dilution. 100 μg 1 to 2 Days
Chien Chèvre Inconjugué EIA, IHC (p)   0.1 mg 11 Days
Humain Chèvre Inconjugué ELISA, WB   0.1 mg 2 to 3 Days
Humain Lapin Inconjugué EIA, WB   0.1 mg 4 to 8 Days
Humain Lapin Inconjugué IP, WB Western blot analysis of extracts of mouse lung, using TET2 antibody (ABIN1875061) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 90s. 100 μL 11 to 13 Days

anti-TET2 Anticorps mieux référencés

  1. Human Monoclonal TET2 Primary Antibody pour IP, WB - ABIN2668527 : Wallner, Schröder, Leitão, Berulava, Haak, Beißer, Rahmann, Richter, Manke, Bönisch, Arrigoni, Fröhler, Klironomos, Chen, Rajewsky, Müller, Ebert, Lengauer, Barann, Rosenstiel, Gasparoni, Nordström et al.: Epigenetic dynamics of monocyte-to-macrophage differentiation. ... dans Epigenetics & chromatin 2016 (PubMed)
    Show all 2 Pubmed References

  2. Human Polyclonal TET2 Primary Antibody pour ICC, IF - ABIN4358585 : Fischer, Miles: Silencing HIF-1α induces TET2 expression and augments ascorbic acid induced 5-hydroxymethylation of DNA in human metastatic melanoma cells. dans Biochemical and biophysical research communications 2017 (PubMed)
    Show all 2 Pubmed References

  3. Human Polyclonal TET2 Primary Antibody pour IHC, ELISA - ABIN571057 : Orr, Haffner, Nelson, Yegnasubramanian, Eberhart: Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. dans PLoS ONE 2012 (PubMed)

  4. Human Polyclonal TET2 Primary Antibody pour IHC, WB - ABIN6688590 : Yu, Liu, Liu, Wang, Liu, Miao, Du, Yang: Ascorbic acid induces global epigenetic reprogramming to promote meiotic maturation and developmental competence of porcine oocytes. dans Scientific reports 2018 (PubMed)

  5. Human Polyclonal TET2 Primary Antibody pour ELISA, IHC - ABIN4358584 : Langemeijer, Kuiper, Berends, Knops, Aslanyan, Massop, Stevens-Linders, van Hoogen, van Kessel, Raymakers, Kamping, Verhoef, Verburgh, Hagemeijer, Vandenberghe, de Witte, van der Reijden, Jansen: Acquired mutations in TET2 are common in myelodysplastic syndromes. dans Nature genetics 2009 (PubMed)

Plus d’anticorps contre TET2 partenaires d’interaction

Human Tet Methylcytosine Dioxygenase 2 (TET2) interaction partners

  1. The results indicate that restoring TET2 function through SIRT1 activation represents a promising means to target Myelodysplastic syndrome (MDS) hematopoietic stem/progenitor cells (HSPCs).

  2. We identified TET2 epigenetic enzyme as a key factor controlling slow-cycling cancer cell (SCCC) numbers, survival, and tumor recurrence. 5-Hydroxymethylcytosine, generated by TET2 enzymatic activity, labeled the SCCC genome in carcinomas and was a predictive biomarker of relapse and survival in cancer patients.

  3. The findings indicated that down-regulation of TET2 expression was a common event and acted as a prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia patients.

  4. The methylation level is reduced in the villi of women with unexplained recurrent spontaneous abortion, which may be correlated with up-regulated expression of DNMT1 and DNMT3b and down-regulated expression of TET1 and TET2.

  5. Contrary to previous reports, no association was found between TET2 mutations and hypomethylating agents treatment response in MDS.

  6. TET2 mutation had adverse impacts on survival and treatment response in acute myeloid leukemia patients and will contribute to risk-stratification, prognosis prediction and therapy guidance.

  7. TET2 deficiency leads initially to stem cell factor (SCF)-dependent hyperproliferation and impaired differentiation of human colony-forming unit-erythroid (CFU-E) cells, which were reversed by a c-Kit inhibitor.

  8. The anti-inflammatory actions of Vicenin-2 are associated not only with increased IL-10 and IL-1Ra expression, but also with TET-2 up-regulation.

  9. TET2-dependent DNA demethylation might play an important role in dental pulp inflammation as an epigenetic regulator.

  10. we demonstrated that DNMT3A and TET2, the 2 most frequently mutated genes in CHIP, have distinctive patterns of hematopoietic cell involvement and a different myeloid proliferation bias.

  11. Promyeloctic leukemia protein recruits TET2, regulating DNA modification and cell proliferation in response to chemotherapeutic agents.

  12. Mutations in TET2 gene and its founder defect induces phenotypic shifts toward dysplasia, myeloproliferation, or progression to acute myeloid leukemia.

  13. People with TET rs2454206 G/A genotype and TET2rs12498609 G/C genotypewere related to lower prevalence of myelodysplastic syndromes (MDS). Both SNPs were associated with certain laboratory features in MDS patients

  14. Data showed that TET2 was downregulated in glioblastoma multiforme (GBM) and was involved in miR-19a-mediated proliferation and metastasis by directly being targeted. Its ectopic overexpression remarkably abrogated the facilitative effect of miR-19a on GBM. These findings indicated that TET2 worked as an anti-oncogene in GBM. Also, the expression of TET2 was positively regulated by AC016405.3.

  15. PSPC1 and TET2 contribute to ERVL and ERVL-associated gene regulation by both transcriptional repression via histone deacetylases and post-transcriptional destabilization of RNAs through 5hmC modification.

  16. A functional interplay between TET2 and p53 during anti-cancer therapy, establishes the rationale for targeting TET2 to overcome chemotherapy resistance associated with mutant p53 tumors.

  17. findings define a novel 'phospho-switch' that regulates TET2 stability and a regulatory pathway that links glucose and AMPK to TET2 and 5hmC, which connects diabetes to cancer; data also unravel an epigenetic pathway by which metformin mediates tumour suppression; thus, this study presents a new model for how a pernicious environment can directly reprogram the epigenome towards an oncogenic state

  18. 5-hydroxymethylation of the EBV genome regulates the latent to lytic switch.

  19. TET2 mutation appeared not to have additional effects when combined with SF3B1, and patients with double mutation appeared to have at least as, good as or even better prognosis than patients with isolated mutation.

  20. these findings provide insight into the interplay between epigenetic modulators and transcription factor activity in hematological neoplasia, but do not confirm the putative role of TET2 in atherosclerosis.

Mouse (Murine) Tet Methylcytosine Dioxygenase 2 (TET2) interaction partners

  1. Consistent with this finding, ablation of the DNA demethylase Tet2 almost completely abolishes cell reprogramming.

  2. Tet2 silencing promoted hematopoietic cell expansion and AngII-induced cardiac dysfunction in mice.

  3. results indicate that restoring TET2 function through SIRT1 activation represents a promising means to target Myelodysplastic syndrome (MDS) hematopoietic stem/progenitor cells (HSPCs)

  4. Tet2 epigenetically activated cell-cycle-inhibiting genes p21 and p27.

  5. Tet2 deficiency in hematopoietic cells is associated with greater cardiac dysfunction in murine models of heart failure.

  6. TET2 localizes to regions of open chromatin and cell-type-specific enhancers. Loss of TET2 leads to attenuation of chromatin binding of the basic helix-loop-helix transcription factors.

  7. Study in mice lacking Tet2 and Tet3 in T-reg cells indicate that Tet2 and Tet3 are guardians of T-reg cell stability and immune homeostasis.

  8. These data identify Tet2 as a key molecular mediator of neurogenic rejuvenation.

  9. Consistent with this, TET2 was required for Rosi-dependent gene activation of certain Rosiglitazone targets accompanied by changes in DNA demethylation at the promoter regions

  10. Pluripotency transcription factors and Tet1/2 maintain Brd4-independent stem cell identity in mouse embryonic stem cells.

  11. Oncogenic N-Ras and Tet2 haploinsufficiency collaborate to dysregulate hematopoietic stem and progenitor cells.

  12. our data establish that Tet2 deficiency predisposes to mature B-cell malignancies, which development might be attributed in part to AID-mediated accumulating mutations and BCR-mediated signaling.

  13. Foxo3a physically interacts with Tet2 and regulates the expression of genes related to adult neural stem cells proliferation.

  14. These results highlight the critical role of TET2 in the maintenance of BMSC functions and osteoblast differentiation and provide evidence that dysregulation of epigenetic modifiers in BMSCs contributes to the progression of myeloid malignancies.

  15. Tet2/Nras double-mutant leukemia showed preferential sensitivity to MAPK kinase (MEK) inhibition in both mouse model and patient samples

  16. Results indicate that tet oncogene 1 protein (Tet1) and tet oncogene 2 protein (Tet2) play a critical role in maintaining bone marrow MSCs (BMMSCs) and bone homeostasis through demethylation of P2X7 purinoceptor (P2rX7) to control exosome and miRNA release.

  17. RHOA G17V expression together with Tet2 loss resulted in development of angioimmunoblastic T cell lymphoma in mice

  18. findings demonstrate the requirement for microbial-dependent inflammation in the development of pre-leukaemic myeloproliferation (PMP) and provide a mechanistic basis for the variation in PMP penetrance observed in Tet2(-/-) mice; this study will prompt new lines of investigation that may profoundly affect the prevention and management of haematopoietic malignancies

  19. Tet2-/- mice develop spontaneous myeloid, T- and B-cell malignancies after long latencies with higher mutation frequencies at genomic sites that gained 5-hydroxymethylcytosine, where Tet2 normally binds.

  20. these results indicate that Tet2 is involved in myoblast differentiation through promoting DNA demethylation and myogenic gene expression.

TET2 profil antigène

Profil protéine

The protein encoded by this gene is a methylcytosine dioxygenase that catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine. The encoded protein is involved in myelopoiesis, and defects in this gene have been associated with several myeloproliferative disorders. Two variants encoding different isoforms have been found for this gene.

Gene names and symbols associated with TET2

  • tet methylcytosine dioxygenase 2 (TET2) anticorps
  • tet methylcytosine dioxygenase 2 (Tet2) anticorps
  • Ayu17-449 anticorps
  • E130014J05Rik anticorps
  • KIAA1546 anticorps
  • MDS anticorps
  • mKIAA1546 anticorps
  • RGD1311625 anticorps

Protein level used designations for TET2

methylcytosine dioxygenase TET2 , probable methylcytosine dioxygenase TET2 , tet oncogene family member 2 , tet oncogene 2

54790 Homo sapiens
478499 Canis lupus familiaris
214133 Mus musculus
310859 Rattus norvegicus
422540 Gallus gallus
100521465 Sus scrofa
538481 Bos taurus
Fournisseurs de qualité sélectionnés pour anti-TET2 (TET2) Anticorps
Avez-vous cherché autre chose?